Baudax Bio, Inc.

Equities

BXRXQ

US07160F4046

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:59:07 2024-04-26 am EDT			5-day change	1st Jan Change
0.0103 ^USD	-8.04%		-2.83%	-53.18%

Feb. 22	Baudax Bio, Inc. Filed for Bankruptcy	CI
2023	Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Baudax Bio, Inc. to Initiate TI-168 Clinical Development

October 18, 2023 at 08:00 am EDT

Baudax Bio, Inc. announced that following recent shareholder approval of corporate actions related to its June 29, 2023 acquisition of TeraImmune, the Company is now poised to initiate clinical development of TI-168, the Company's next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitors. The Company anticipates initiating its Phase 1/2a clinical study of TI-168 in Hemophilia A patients withFVIII inhibitors with a modest initial budget in First Quarter of 2024.

Latest news about Baudax Bio, Inc.

Baudax Bio, Inc. Filed for Bankruptcy	Feb. 22	CI
Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
Baudax Bio, Inc.(OTCPK:BXRX) dropped from S&P TMI Index	Nov. 20	CI
Baudax Bio, Inc.(OTCPK:BXRX) dropped from NASDAQ Composite Index	Nov. 16	CI
Baudax Bio, Inc. to Initiate TI-168 Clinical Development	23-10-18	CI
Sector Update: Health Care Stocks Advancing in Late Afternoon Trading	23-10-06	MT
Sector Update: Health Care Stocks Higher in Afternoon Trading	23-10-06	MT
Baudax Bio Appoints Natalie McAndrew as Interim Finance Chief	23-10-06	MT
Baudax Bio, Inc. Announces Board Changes	23-10-06	CI
Baudax Bio, Inc. Announces Chief Financial Officer Changes	23-10-06	CI
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	23-09-29	MT
Top Premarket Decliners	23-09-29	MT
Baudax Bio, Inc. Announces Orphan Drug Designation Granted by U.S. Fda for Ti-168 for the Treatment of Hemophilia A with Inhibitors	23-09-29	CI
Sector Update: Health Care Stocks Rising in Late Afternoon Trading	23-09-28	MT
Sector Update: Health Care	23-09-28	MT
Top Midday Gainers	23-09-28	MT
Baudax Bio Shares Double After Orphan Drug Designation for TI-168	23-09-28	DJ
Wall Street Set to Open Flat; Q2 GDP Rises 2.1%; Jobless Claims Lower Than Expected	23-09-28	MT
Baudax Bio Files Registration Statement on Behalf of Selling Stockholder	23-09-22	MT
Baudax Bio, Inc. Enters into Amendment No. 7 to the Credit Agreement	23-09-05	CI
Baudax Bio, Inc. announced that it expects to receive $50 million in funding from Alumni Capital LP	23-08-22	CI
Baudax Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Baudax Bio, Inc., Baudax Bio N.A. LLC, Baudax Bio Limited and TeraImmune, LLC enter Amendment No. 1 to Forbearance Agreement and Amendment No. 6 to Credit Agreement	23-07-31	CI
Baudax Bio, Inc. Appoints Yong Chan Kim as A Member of the Board	23-07-05	CI
Certain Common Stock of Baudax Bio, Inc. are subject to a Lock-Up Agreement Ending on 1-JUL-2023.	23-06-30	CI

Chart Baudax Bio, Inc.

Duration

Period

More charts

Company Profile

Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in combination with other non-NSAID analgesics. Its pipeline of other pharmaceutical products includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, which are used as muscle paralyzing agents to facilitate intubation and surgery. Its product pipeline includes NMBAs, which are used as muscle paralyzing agents to facilitate intubation and surgery. It is developing intermediate-acting NMBA, BX-1000, an ultrashort-acting NMBA, BX-2000, and a reversal agent specific to its NMBAs. It is also focused on the discovery and development of Treg-based cell therapies for autoimmune diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
BAUDAX BIO, INC.	-53.18%	540K
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research

Baudax Bio, Inc.

Equities

BXRXQ

US07160F4046

Biotechnology & Medical Research

Baudax Bio, Inc. to Initiate TI-168 Clinical Development

Latest news about Baudax Bio, Inc.

Chart Baudax Bio, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research